Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Anti-TNF artifacts

Johnson & Johnson's Centocor Inc. unit last week became the last company with a marketed anti-TNF alpha drug to add a label warning of an increased risk of hematologic events, perhaps because the rare events have been even more sparse among Remicade

Read the full 425 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE